Approval · Notice of Compliance 2723 · 1998
BROMOCRIPTINE: Notice of Compliance 2723
Issued June 19, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2723
- Date
- June 19, 1998
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Prolactin inhibitor - growth hormone suppressant in acromegaly - adjunctive medication in parkinson's disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BROMOCRIPTINE | 02238192 | Cancelled Post Market |
| BROMOCRIPTINE | 02238193 | Cancelled Post Market |
Medicinal ingredients
- BROMOCRIPTINE MESYLATE 2.5 MG per TAB
- BROMOCRIPTINE MESYLATE 5 MG per CAP